Naveen L Pereira
Overview
Explore the profile of Naveen L Pereira including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
156
Citations
2155
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Taner T, Biggins S, Cummins N, Daly R, Dietz A, Emamaullee J, et al.
Mayo Clin Proc
. 2025 Mar;
PMID: 40057871
The number of highly sensitized patients in need of a multiorgan transplant is increasing. Criteria informing their transplant candidacy, approaches to management on the waitlist, and protocols related to alloantibody...
2.
3.
Fazzini L, Castrichini M, Bois M, Natt N, Chang I, Grogan M, et al.
Mayo Clin Proc
. 2024 Dec;
99(12):2008-2011.
PMID: 39631992
No abstract available.
4.
Fazzini L, Hubers S, Cao J, Scott C, McCully R, Castrichini M, et al.
J Am Soc Echocardiogr
. 2024 Nov;
PMID: 39613116
Background: During exercise stress echocardiography (ESE), there are patients with normal left ventricular ejection fraction (LVEF) who paradoxically develop reduced LVEF during exercise despite absence of coronary artery disease (CAD)...
5.
Fazzini L, Casula M, Cau R, Figueiral M, Castrichini M, Binaghi G, et al.
Am J Cardiol
. 2024 Nov;
238:32-39.
PMID: 39608556
The absence of late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) is commonly used to distinguish takotsubo syndrome (TTS) from other myocardial diseases. However, case series have reported the...
6.
Angiolillo D, Galli M, Alexopoulos D, Aradi D, Bhatt D, Bonello L, et al.
JACC Cardiovasc Interv
. 2024 Nov;
17(22):2639-2663.
PMID: 39603778
Current evidence indicates that dual antiplatelet therapy with aspirin plus a P2Y inhibitor is essential for the prevention of thrombotic events after percutaneous coronary interventions. However, dual antiplatelet therapy is...
7.
Ingraham B, Huxley S, Lane C, Gulati R, Lewis B, Jaffe A, et al.
Mayo Clin Proc
. 2024 Nov;
100(1):94-108.
PMID: 39601743
Objective: To test the feasibility and safety of genotype guidance in the selection of P2Y monotherapy within 1 week of percutaneous coronary interventions (PCIs) among patients with high bleeding risk...
8.
Figueiral M, Paldino A, Fazzini L, Pereira N
Curr Heart Fail Rep
. 2024 Oct;
21(6):554-569.
PMID: 39405019
Purpose Of Review: This review aims to provide a comprehensive overview of the current understanding of genetic markers associated with heart failure (HF) and its underlying causative diseases, such as...
9.
Figueiral M, Paldino A, Machado Bressan Wilke M, Farris J, Verheijen J, Giudicessi J, et al.
Mayo Clin Proc
. 2024 Oct;
99(11):1732-1743.
PMID: 39387793
Objective: To determine the prevalence, penetrance, and disease expression of cardiomyopathy-related genetic variants in an unselected, richly phenotyped Mayo Clinic population in the setting of preemptive sequencing, with return of...
10.
Huxley S, Moriarty J, Hlatky M, Lennon R, Bailey K, Bell M, et al.
Pharmacogenomics J
. 2024 Oct;
24(6):32.
PMID: 39379363
CYP2C19 loss of function (LOF) carriers undergoing percutaneous coronary intervention (PCI) have an increased risk of ischemic events when treated with clopidogrel. PCI patients in TAILOR-PCI were randomized to clopidogrel...